Valuation: Exact Sciences Corporation

Market Cap 20.03B 17.35B 16.25B 14.82B 27.9B 1,910B 28.36B 191B 74.64B 956B 75.19B 73.55B 3,190B P/E 2024
-10.1x
P/E 2025 -92.2x
Enterprise Value 21.6B 18.72B 17.52B 15.99B 30.08B 2,060B 30.59B 205B 80.49B 1,031B 81.09B 79.32B 3,440B EV / Sales 2024
4.4x
EV / Sales 2025 6.42x
Free-Float
98.24%
Yield 2024 *
-
Yield 2025 -
1 day+0.95%
6 months+1.43%
Current year+3.30%
Current year 101.51
Extreme 101.51
104.98
1 year 42.02
Extreme 42.02
104.98
3 years 38.81
Extreme 38.8118
104.98
5 years 29.27
Extreme 29.27
108.99
10 years 13.05
Extreme 13.05
159.54
Date Insider Type Main position Quantity % Market Cap.
3/23/26 Free

Head of Human Resources

329,891 0.1728%
3/23/26 Issuer sale

General Counsel

93,932 0.0492%
2/27/26 Fiscal year

Chief Executive Officer

168,201 0.0882%
Change 5-day change 1-year change 3-year change Capi.($)
+0.95%-.--%+156.44%+27.36% 20.03B
-0.24%+3.42%+108.97%+303.02% 4.06B
+0.30%0.00%+65.81%+84.53% 3.72B
+1.41%+48.85%+229.44%-8.07% 2.9B
+0.34%+0.30%+301.27%+430.67% 2.44B
+1.43%+5.85%-22.03%-29.93% 2.31B
+4.22%+6.51%+9.93% - 1.31B
+5.85%+16.46%+17.72%+46.95% 988M
-4.28%-9.64%+182.04%-43.81% 904M
+5.70%+10.67%-33.71%+0.79% 541M
Average +1.57%+27.25%+101.59%+90.17% 3.92B
Weighted average by Cap. +0.97%+64.71%+136.35%+80.67%

Financials

2024 2025
Net sales 2.76B 2.39B 2.24B 2.04B 3.84B 263B 3.91B 26.24B 10.28B 132B 10.36B 10.13B 439B 3.25B 2.81B 2.63B 2.4B 4.52B 310B 4.6B 30.89B 12.1B 155B 12.19B 11.93B 517B
Net income -1.03B -892M -835M -762M -1.43B -98.13B -1.46B -9.79B -3.83B -49.12B -3.86B -3.78B -164B -208M -180M -169M -154M -290M -19.83B -295M -1.98B -775M -9.93B -781M -764M -33.12B
Net Debt 1.74B 1.51B 1.41B 1.29B 2.42B 166B 2.46B 16.53B 6.48B 82.96B 6.52B 6.38B 277B 1.57B 1.36B 1.27B 1.16B 2.19B 150B 2.22B 14.94B 5.85B 74.96B 5.9B 5.77B 250B
Logo Exact Sciences Corporation
Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. It offers a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. Its portfolio includes brands such as Cologuard and Oncotype DX, along with solutions like Cancerguard for blood-based analysis of molecular information across multiple cancers and Oncodetect for molecular residual disease and recurrence monitoring. Its flagship screening products, the Cologuard and Cologuard Plus tests, are patient-friendly, non-invasive, stool-based DNA (sDNA) screening tests that utilize a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Its Cancerguard test is designed to detect multiple cancers in their earliest stages from a single blood draw. It offers predefined genetic tests for all clinically relevant genes, and whole genome (PGnome) sequencing tests.
Employees
7,150
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
AAA
  1. Stock Market
  2. Stocks
  3. EXAS Stock